Review article · 2025 · Open access
Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
Antibody Therapeutics, 9(1), 58–69 · Published 20 December 2025 · DOI 10.1093/abt/tbaf026
In brief
“Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy” is a 2025 review article by Xiaoqiang Kang and 3 co-authors, published in Antibody Therapeutics. OpenAlex counts 11 citations as of 18 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Antibody Therapeutics.
- Citations
- 11
- Most cited in
- 2026 (11)
- Field-weighted impact
- 0.73
- References
- 96
- Authors
- 4
Abstract
T-cell engagers (TCEs) represent an emerging class of immunotherapies that harness T cells' cytotoxic power to eliminate diseased cells-a transformative future therapeutic strategy. TCEs form immunological synapses to trigger potent immune responses, with proven efficacy in blood cancers; research expands their use to solid tumors via innovative molecular design and improved safety profiles. Beyond oncology, TCEs hold promise in autoimmune disorders by eliminating autoreactive cells, offering novel avenues for diseases like lupus. However, achieving optimal outcomes without disrupting immune homeostasis remains a challenge. Key obstacles-on-target off-tumor toxicity, cytokine release syndrome, tumor antigen loss, and T cell exhaustion-limit broader adoption. Current research addresses these via enhanced specificity, optimized design, improved druggability, and synergistic combinations. This review analyzes TCEs' mechanisms, challenges, innovations and applications, highlights our pipeline advances, and advocates sustained innovation to broaden TCE use across diseases.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kang, X., Zhao, Y., Ling, H., & Huang, X. (2025). Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. Antibody Therapeutics, 9(1), 58–69. https://doi.org/10.1093/abt/tbaf026
MLA 9
Kang, Xiaoqiang, et al. “Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy.” Antibody Therapeutics, vol. 9, no. 1, 2025, pp. 58–69. https://doi.org/10.1093/abt/tbaf026.
Chicago
Kang, Xiaoqiang, Yue Zhao, Hong Ling, and Xiao Huang. 2025. “Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy.” Antibody Therapeutics 9 (1): 58–69. https://doi.org/10.1093/abt/tbaf026.
Harvard
Kang, X. et al. (2025) ‘Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy’, Antibody Therapeutics, 9(1), pp. 58–69. doi:10.1093/abt/tbaf026.
IEEE
X. Kang, Y. Zhao, H. Ling, and X. Huang, “Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy,” Antibody Therapeutics, vol. 9, no. 1, pp. 58–69, 2025, doi: 10.1093/abt/tbaf026.
BibTeX
@article{kang2025bispecific,
title = {{Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy}},
author = {Kang, Xiaoqiang and Zhao, Yue and Ling, Hong and Huang, Xiao},
journal = {Antibody Therapeutics},
year = {2025},
volume = {9},
number = {1},
pages = {58--69},
doi = {10.1093/abt/tbaf026},
url = {https://doi.org/10.1093/abt/tbaf026}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- T-cell engagers
- bispecific T-cell engagers
- solid tumors
- hematologic malignancies
- autoimmune disease
- lupus
- on-target off-tumor toxicity
- cytokine release syndrome
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Kang, X., Zhao, Y., Ling, H., & Huang, X. (2025). Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. Antibody Therapeutics, 9(1), 58–69. https://doi.org/10.1093/abt/tbaf026
How many times has this paper been cited?
11 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Antibody Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Xiaoqiang Kang, Yue Zhao, Hong Ling, Xiao Huang.
What is the DOI of this paper?
10.1093/abt/tbaf026, permanently at https://doi.org/10.1093/abt/tbaf026. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.